Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Henry Ford Health System Adopts Healthy Interactions Conversation Map(R) Education Program As Standard Curriculum In Diabetes Education
Henry Ford Health System, one of the nation"s top rated health systems and recognized visionaries in offering quality care, formally announced its adoption of Healthy Interactions U.S. Diabetes Conversation Map® education program in its diabetes education curriculum, proclaiming them to demonstrate increased effectiveness in helping patients with diabetes live with their condition. The five Conversation Map tools, which were developed in collaboration with the American Diabetes Association and sponsored by Merck & Co., are based around large colorful 5 ft by 3 ft discussion displays.
generic viagra online
Successful Disease Management Programs Can Play Role In Health Care Reform
A study of the award-winning Behavioral Pharmacy Management Program (BPM) shows the private-public Medicaid partnership program has helped improve patient care while saving eight states almost $95 million in behavioral health pharmaceutical costs. Lilly funds the program, which is designed and run by research firm Comprehensive NeuroScience, Inc. (CNS) at the sole direction and guidance of state Medicaid departments. The BPM, which has been executed in more than half of the states, has won a variety of national awards, including the Substance Abuse and Mental Health Services Administration Science and Service Award, URAC Silver Award for Best Practices in Consumer Empowerment and Protection, American Psychiatric Association Bronze Achievement Award and Disease Management Association of America Gold Award.
News of the day
FDA Approval For Cetirizine Hydrochloride Tablets (OTC) ANDA - Hay Fever And Other Respiratory Allergies
Taro Pharmaceutical Industries Ltd. reported that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for cetirizine hydrochloride tablets (OTC), 5 mg and 10 mg ("Cetirizine Tablets"). The product will be marketed by Taro"s U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc.
Diagnostics

New Clinical Research Organization Established In West Palm Beach, Florida

Executive vice president is pharmaceutical industry veteran Arthur Simon, Ph.D. Though new in name, Palm Beach CRO - a clinical research organization recently formed in West Palm Beach, Florida - is headed by a veteran pharmacologist and clinical research executive: Arthur Simon, Ph.D. Palm Beach CRO is an outgrowth of Palm Beach Research Center, a contract clinical research facility that has conducted more than 500 clinical trials in its 15-year history and has worked with more than 110 pharmaceutical companies. Palm Beach CRO was created in December of 2008, and Dr. Simon named as executive vice president, to offer pharmaceutical companies and their executives a new option for outsourcing the overall management and supervision of clinical trials, including multi-center trials. Services provided by Palm Beach CRO run the gamut from site evaluation, protocol preparation and site documentation to site closeout and data management and analysis. As executive vice president, Dr. Simon brings more than 30 years of pharmaceutical research and development experience to the position. He spent 24 years as president and CEO of Research Testing Laboratories, Inc. in Great Neck, NY, a hybrid research company consisting of a site management organization (SMO) and a contract clinical research organization (CRO) with more than 100 employees. Dr. Simon directed all aspects of RTL"s clinical research activities for Rx, OTC, biotechnology, nutraceuticals, and medical devices. "We"re pleased to have an industry veteran of the caliber of Art Simon to lead this new clinical research organization," says David Scott, MBA, CCRC, chief executive officer of Palm Beach Research Center. "His wide-ranging expertise and high level of accomplishment in the industry offer excellent value to pharmaceutical executives as they out their clinical trials." More about Dr. Simon Prior to his tenure with RTL, Dr. Simon served as director of cardiovascular clinical research for the International Division of Bristol Myers Squibb Company in New York, NY, where he was responsible for worldwide clinical programs in diuretics, beta-blockers, anti-arrhythmics, and anti-hyperlipidemia agents. Dr. Simon earned his undergraduate degree in biology at the Philadelphia College of Pharmacy and Science. He earned a master of science degree in physiology at Fairleigh Dickinson University and a doctorate in pharmacology at the University of Cincinnati College of Medicine. Palm Beach CRO


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009